MarketBeat reports consensus rating for Harvard Bioscience, which is listed on Nasdaq. Benchmark has boosted its target price for the company's stock.
2 reports, 2 independent
Updated Aug 12
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat reports consensus rating for Harvard Bioscience, which is listed on Nasdaq. Benchmark has boosted its target price for the company's stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Harvard Bioscience
company in Holliston, United States
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
- CervoMed and Elanco Animal Health Incorporated are being compared as healthcare companies, with CervoMed being listed on Nasdaq.
- Global market sentiment is being influenced by geopolitical conflict in the Middle East, impacting the competitive landscape of diabetes and obesity drug companies like Novo Nordisk and Eli Lilly.
-
Benchmark
venture capital firm
-
MarketBeat
American personal finance blog
Related events
- BioPharma stock was traded on the NASDAQ stock exchange on July 30, 2026, with its performance tracked by financial blogs.
- MarketBeat reported a consensus rating for SKYX Platforms, a company listed on the Nasdaq exchange.
- MarketBeat reported the consensus stock rating for Wheeler Real Estate Investment Trust, Inc.
- MarketBeat reported the consensus rating for Mammoth Energy Services, Inc. on October 24, 2026.
- MarketBeat provided stock ratings for Paylocity Holding Corporation, alongside SEC filings and price target updates from Cantor Fitzgerald and Citizens Jmp.